Evotec SE (NASDAQ:EVO) Short Interest Update

Evotec SE (NASDAQ:EVO) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 449,700 shares, a growth of 104.3% from the October 31st total of 220,100 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 195,200 shares, the days-to-cover ratio is currently 2.3 days.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on EVO shares. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. Jefferies Financial Group lowered shares of Evotec from a “buy” rating to a “hold” rating and reduced their target price for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Evotec in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.93.

Institutional Investors Weigh In On Evotec

Several hedge funds have recently made changes to their positions in EVO. Novo Holdings A S acquired a new position in Evotec in the 2nd quarter valued at $71,183,000. Wellington Management Group LLP boosted its holdings in shares of Evotec by 29.7% in the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after acquiring an additional 602,858 shares in the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Evotec during the third quarter worth about $512,000. DCF Advisers LLC lifted its position in Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares during the period. Finally, Clear Harbor Asset Management LLC purchased a new stake in Evotec in the 3rd quarter valued at approximately $104,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Trading Down 2.9 %

Shares of EVO stock traded down $0.14 during trading hours on Friday, hitting $4.69. The stock had a trading volume of 64,435 shares, compared to its average volume of 134,065. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The stock’s 50 day moving average is $3.95 and its 200 day moving average is $4.19. Evotec has a twelve month low of $2.85 and a twelve month high of $12.00.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.